$VC

Royal Bank Of Canada Lowers Visteon (NASDAQ:VC) Price Target to $129.00

Royal Bank of Canada lowered its Visteon (NASDAQ:VC) price target to $129 from $130 and kept an “outperform” rating, citing an estimated 21.41% upside. Other analysts set targets ranging from $118 to $134. Visteon shares rose to $106.25. Q2 results showed EPS of $1.91 vs $2.21 expected on revenue of $960M.

Original reporting
Published Jul 24, 2026, 4:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 24, 2026, 10:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Royal Bank Of Canada Lowers Visteon (NASDAQ:VC) Price Target to $129.00 — source image
Decision brief

The 30-second read

$VCNeutralLow
01

Why it matters

For traders, the actionable signal is the direction of the valuation revision (down slightly) without a rating downgrade, which typically produces muted price reaction unless the market is already re-pricing the stock aggressively.

02

Market read

A modest PT reduction with unchanged “outperform” rating, in the context of a recent EPS miss and ongoing buyback activity.

03

What to watch

The article also notes an EPS miss versus consensus and a large accelerated buyback, which may matter more than the one-dollar PT change for near-term trading.

Relevance 4/10Novelty 4/10Timing: after-hours/late-day analyst note coverage (published 2026-07-24 16:02 UTC)

Background

The piece centers on an RBC analyst note lowering Visteon’s price objective by $1, alongside a recap of recent earnings and other analyst target changes.

Company-level read

Ticker impact

$VCNeutralMedium confidence
Context

RBC cut Visteon’s price target to $129 from $130 while keeping an “outperform” rating, implying a modest valuation reset.

Expected impact

Likely limited near-term impact; could slightly cap upside expectations unless paired with new fundamentals.

Evidence & confidence

The article provides a specific PT reduction and reiterates “outperform,” with no new company-specific operational disclosure beyond the already-referenced earnings context.

Market effects

Limited read-across to auto-parts suppliers; this is a single-name valuation adjustment rather than a sector catalyst.

None indicated.

None indicated.

Counterpoint

The PT cut could be interpreted as caution after the recent earnings miss, even if the rating stays “outperform.”

Key entities

  • Visteon

    NASDAQ-listed automotive electronics supplier; subject of the price-target change and recent earnings recap.

  • Royal Bank of Canada

    Issued the research note lowering Visteon’s price target to $129 while maintaining “outperform”.

Related articles

Med

Visteon Corporation Q3 2026 Earnings Call Summary

Visteon Corporation reported Q3 2026 earnings, highlighting 10 percentage points of market outperformance despite a 5% decline in vehicle production. The company addressed $77 million in warranty charges and managed inflation in PCBs. For 2027, Visteon anticipates $500 million in incremental costs and aims to maintain EBITDA targets through customer recoveries. China sales are expected to grow in Q4 2026, driven by high-performance compute launches.

Med

Visteon (VC) Q3 2026 Earnings Call Transcript

Visteon (VC) reported Q3 2026 earnings, highlighting a $200M share repurchase and sales growth despite market challenges. Sales grew in Americas, Europe, and Asia (excluding China), with China sales expected to recover in Q4. The company launched 21 new products, including high-value cockpit technologies, and secured $1B in new business bookings, targeting $6B for the year. Strategic wins include programs with Toyota, Maruti Suzuki, and Tata Motors.

$VCMedAI 8/10

What Visteon (VC) Said on Its Q3 Earnings Call

Visteon (VC) reported Q3 earnings, noting regional sales trends and product launches. Sales rose 14% in Asia excluding China, but faced challenges in the Americas and China. The company expects China sales to grow in Q4 with new launches. Visteon launched 21 products and booked $1B in new business, maintaining its $6B annual target. It updated guidance, raising full-year sales to $3.8B-$3.85B but lowering adjusted EBITDA to $370M-$410M. Q4 sales are expected to be $940M, flat YoY.